Table of Contents: CATIE TreatmentUpdate - 2001


Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 115: February - Vol. 12, No. 11

English  Françaises

 St. John's wort found to lower nevirapine levels

 Baisse du taux de névirapine sous l'effet du millepertuis

HoseinSR
St. John's wort (Hypericum perforatum) is a common herbal remedy used to treat mild to moderate depression. About a year ago, we reported findings that St. John's wort may interact with certain drugs used to treat HIV infection.

 Are deaths due to liver damage becoming more common?

 Les décès attribuables aux dommages hépatiques sont-ils à la hausse?

HoseinSR
After receiving reports of increased deaths due to liver disease in PHAs, a team of doctors in Boston decided to review medical records at its hospital to find out if more PHAs were indeed dying of complications from liver disease. The doctors looked at data from three points in time — 1991, 1996 and 1998-1999.

 St. John's wort extract found not helpful for hepatitis C

 Le millepertuis s'avère inutile contre l'hépatite C

HoseinSR
The plant St. John's wort (Hypericum perforatum) is used for the treatment of mild to moderate depression. Hypericin is a compound found in the stems and petals of the flowers of St. John's wort. Over the past decade, research teams in Canada, the U.S., Israel and Europe have been conducting lab experiments using hypericin and other compounds extracted from St. John's wort. In these experiments, hypericin has shown activity against viruses that cause herpes, AIDS and diseases similar to hepatitis in animals. Based on these results, researchers in New York decided to conduct a study to find out about hypericin's antiviral effect in people with hepatitis C virus (HCV). According to the results, hypericin taken orally for two months had no detectable anti-HCV activity, but it caused "considerable" temporary side effects.

 Canadian researchers study "immune healing"

 Des chercheurs canadiens tentent de guérir le système immunitaire

HoseinSR
Shortly after entering the body, HIV begins to damage the ability of the immune system to fight microbes in general and HIV in particular. A major focus of AIDS research is to find a way to restore the immune system's ability to fight HIV.

 Kaletra approved in Canada

 Kaletra est approuvé au Canada

HoseinSR
On Friday March 9, 2001, Health Canada granted permission to Abbott Laboratories for the sale of Kaletra (a combination of the protease inhibitors lopinavir/ritonavir), formerly known as ABT-378/r, for the treatment of HIV infection in adults and children six months or older. Kaletra was approved for sale in the U.S. in September 2000.

Table Of Contents

TreatmentUpdate 123: November/December - Vol. 13, No. 7
Can delavirdine substitute for ritonavir?; Hepatitis C treatment, HAART and side effects; Toxicity profile of HAART; Rosiglitazone for lipodstrophy?; Actos (pioglitazone); Focus on fat; Metformin — long-term results; Sugar blues and protease inhibitors; Glucose — from food to blood sugar; Lipodystrophy - introduction; Caution with nelfinavir and some lipid-lowering drugs; Trizivir approved in Canada;

TreatmentUpdate 122: October - Vol. 13, No. 6
Looking at soluble CD23 levels to predict lymphoma; Cidofovir for KS lesions; Can low-dose shark cartilage make Kaposi's sarcoma disappear?; Chemo and HAART extend survival with lymphoma; Encouraging news on lymphoma from France; AIDS and lymphoma; New formulation of ddI approved in Canada — Videx EC; Expanded access to tenofovir

TreatmentUpdate 121: September - Vol. 13, No. 5
SIDE EFFECTS - Andractim for HAART-associated breast enlargement; SIDE EFFECTS - Does efavirenz cause breast enlargement?; IMMUNE BOOSTERS - Interleukin-12 may be useful for hepatitis C; ANTI-HIV AGENTS - Study finds HIV subtly damages vision; ANTI-HIV AGENTS - Searching for the right dose of ritonavir-saquinavir; ANTI-HIV AGENTS - Different combinations of ritonavir-indinavir

TreatmentUpdate 120: August - Vol. 13, No. 4
Depression linked to immune system decline in women; Carnitine for high triglycerides; Lipid-lowering drugs and changes to diet can make a difference; Sexual dysfunction and HAART; Immune booster used to fight drug-resistant herpes; Effect of HAART on cervical growths; Switching to nevirapine — results after one year

TreatmentUpdate 119: July - Vol. 13, No. 3
Fosamax for HIV-related bone problems?; Indinavir and bones: Does thickness = strength?; Lipodystrophy — nukes vs. protease inhibitors; Spanish study looks at nevirapine's effect on the liver; Pesticides found in many ginseng supplements in the U.S.; Can ginseng help suppress HIV?; Large Italian study looks at when to start HAART;

TreatmentUpdate 118: June - Vol. 13, No. 2
Protease inhibitors and blood sugar problems; Indinavir - effect on sugar and insulin; Background on glucose — from food to blood sugar; Extra co-enzyme Q10 for statin-users?; Can vitamin E help people recover from hepatitis B?; Study examines link between low levels of zinc and survival; Zinc and the immune system;

TreatmentUpdate 117: May - Vol. 13, No. 1
Bone damage - more than just nukes involved; Australian study links nukes, lactic acid to bone loss;High levels of lactic acid in some users of HAART ;Nukes may be linked to hearing loss; Of power plants and energy shortages; German study finds whey protein supplement boosts antioxidants; Spanish doctors try switching therapy from month to month

TreatmentUpdate 115: February - Vol. 12, No. 11
St. John's wort found to lower nevirapine levels; Are deaths due to liver damage becoming more common?; St. John's wort extract found not helpful for hepatitis C; Canadian researchers study "immune healing"; Kaletra approved in Canada;

TreatmentUpdate 114: January - Vol. 12, No. 10
Some women may be at high risk for anal cancer; DHEA — Cautions and concerns; DHEA for depression?; Changes in DHEA levels in people taking anti-HIV therapy; DHEA — Background; Nukes linked to fat wasting; Triple nuke therapy — results after one year; Switching meds: from protease inhibitors to non-nukes

Copyright / Staff / How to Contact
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.